Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu, Y, Karaca, M, Zhang, Z, Gioeli, D, Earp, H S, Whang, Y E·2010·Oncogene
DOI 10.1038/onc.2010.103

Cited by (108)

Items 101–108 of 108

  1. Small Molecule Therapeutics Targeting Ligand-Independent Activation of Androgen Receptor in Prostate Cancer
    Sandipan Das, Amlan Ghosh · 2024 · Springer eBooks
  2. Rôle de CRIPTO dans la transition épithéliale-mésenchymateuse du cancer de la prostate et son impact sur la modulation de la communication intercellulaire
    Ihsan El Sayed Hussein Jomaa · 2016
  3. Identification de nouveaux inhibiteurs de kinases pour le traitement des cancers de prostate résistants à la castration
    Joëlle Azzi · 2016
  4. DrugPlayGround: Benchmarking Large Language Models and Embeddings for Drug Discovery
    Tianyu Liu, Sihan Jiang, Fan Zhang, Kunyang Sun, Teresa L. Head-Gordon, Hongyu Zhao · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  5. BindingDB Entry 50045838: Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.
    BindingDB · 2016 · UC San Diego
  6. BindingDB Entry 50019694: Design, Synthesis, and Evaluation of (
    BindingDB · 2024 · UC San Diego
  7. BindingDB Entry 50019151: Small Molecules Targeting Activated Cdc42-Associated Kinase 1 (ACK1/TNK2) for the Treatment of Cancers.
    BindingDB · 2024 · UC San Diego
  8. Inhibition of the IL-6/STAT3 signaling pathway for therapeutic intervention in prostate carcinogenesis and cancer cell differentiation
    Anne Schröder, Richard Jove · 2013 · RWTH Publications (RWTH Aachen)